DB-1310 by Duality Biologics (Shanghai) for Non-Small Cell Lung Cancer: Likelihood of Approval

DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Non-Small Cell Lung Cancer.

New insights into immune mechanisms that prevent cancer metastasis

Metastatic disease-;when cancer spreads from the primary tumor to other parts of the body-;is the cause of most cancer deaths.

October 7, 2024

Differentiated approach in CVD with potential – Biotech Investments

Edison Investment Research Limited Edison issues initiation on Cereno Scientific (CRNO B): Differentiated approach in CVD with potential 22-Feb-2024 / 12:36 GMT/BST The issuer is

February 23, 2024

Teen Vaping Linked to Higher Lead, Uranium Levels

Teens with more frequent vaping had increased urine lead and uranium levels, researchers found. Among 200 individuals ages 13 to 17, those who vaped intermittently

April 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.